Magenta Therapeutics, Inc. MGTA
0.70 0.00 (+0.00%)
At closeSep 11, 2023, 4:00 PM EDT
0.69 Day range 0.7589
0.32 52-week range 2.22
Analyst view
Consensus: hold
Hold
Price target (mean) 1.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 1
- 2 months ago 2
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.19 | -0.19 – -0.19 | -0.29 | +34.5% | 0 | 0.0% | 1 |
| Next quarter | -0.15 | -0.15 – -0.15 | -0.27 | +44.4% | 0 | 0.0% | 1 |
| Current year | -0.82 | -0.82 – -0.82 | -1.29 | +36.4% | 0 | 0.0% | 1 |
| Next year | 0.02 | 0.02 – 0.02 | -0.82 | +102.4% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 28, 2023 | HC Wainwright & Co. | Initiated | — | Neutral |
| Jan 26, 2023 | BTIG | Downgrade | Buy | Neutral |
| Jan 26, 2023 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Jan 26, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Dec 21, 2022 | BTIG | Maintained | — | Buy |
| Aug 25, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| May 24, 2022 | Goldman Sachs | Maintained | — | Buy |
| Apr 18, 2022 | BTIG | Maintained | — | Buy |
| Apr 18, 2022 | Mizuho | Maintained | — | Buy |
| Jan 24, 2022 | B. Riley Securities | Maintained | — | Buy |
| Jan 6, 2022 | Goldman Sachs | Upgrade | Neutral | Buy |
| Aug 3, 2021 | JP Morgan | Downgrade | Overweight | Neutral |
| Jun 29, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 15, 2021 | BTIG | Initiated | — | Buy |
| May 18, 2021 | B. Riley Securities | Initiated | — | Buy |
| Jan 7, 2021 | Mizuho | Initiated | — | Buy |
| Jun 8, 2020 | Goldman Sachs | Upgrade | Neutral | Buy |
| Dec 6, 2019 | BTIG | Initiated | — | Buy |
| Mar 25, 2019 | Goldman Sachs | Downgrade | Buy | Neutral |
| Mar 15, 2019 | Raymond James | Initiated | — | Outperform |
| Jul 16, 2018 | Goldman Sachs | Initiated | — | Buy |
| Jul 16, 2018 | JP Morgan | Initiated | — | Overweight |
| Jul 16, 2018 | Cowen & Co. | Initiated | — | Outperform |
| Jul 16, 2018 | Wedbush | Initiated | — | Outperform |